Lantheus (NASDAQ:LNTH) Trading 7.2% Higher – Time to Buy?

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s share price shot up 7.2% on Monday . The stock traded as high as $78.00 and last traded at $77.80. 1,372,245 shares were traded during trading, an increase of 51% from the average session volume of 910,950 shares. The stock had previously closed at $72.56.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Mizuho lifted their price objective on Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. JonesTrading downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Citizens Jmp lifted their price target on Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a report on Tuesday, February 24th. Truist Financial boosted their price target on shares of Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Finally, Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Tuesday, February 24th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $82.17.

Lantheus Stock Performance

The firm’s fifty day moving average is $69.11 and its 200-day moving average is $60.98. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $5.17 billion, a PE ratio of 23.79 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The business had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. During the same period last year, the business earned $1.59 earnings per share. The business’s revenue for the quarter was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Hedge Funds Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently bought and sold shares of LNTH. Stanley Laman Group Ltd. grew its holdings in shares of Lantheus by 38.7% in the third quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock valued at $4,087,000 after purchasing an additional 22,229 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Lantheus in the third quarter worth $1,847,000. American Assets Inc. acquired a new position in shares of Lantheus in the third quarter worth $872,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Lantheus during the third quarter worth $2,184,000. Finally, Assetmark Inc. raised its stake in shares of Lantheus by 20.1% in the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock valued at $6,078,000 after acquiring an additional 19,844 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.